Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC

Dowler Nygaard,Anneli; Spindler,Karen-Lise Garm; Pallisgaard,Niels; Andersen,Rikke Fredslund; Jakobsen,Anders

doi:10.3892/or.2013.2906

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC

Authors:
- Anneli Dowler Nygaard
- Karen-Lise Garm Spindler
- Niels Pallisgaard
- Rikke Fredslund Andersen
- Anders Jakobsen
View Affiliations

Affiliations: Department of Oncology, Vejle Hospital, DK-7100 Vejle, Denmark, Department of Clinical Biochemistry, Vejle Hospital, DK-7100 Vejle, Denmark
Published online on: December 6, 2013 https://doi.org/10.3892/or.2013.2906
Pages: 969-974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumours in the western world and is associated with a poor prognosis. Biomarkers predicting prognosis and therapeutic effects are highly required, and cell-free DNA (cfDNA) may be a feasible option. Genetic mutations can be analysed in plasma and may increase the scientific use of such measurements. In the present study, we investigated: i) the dynamics of cfDNA and plasma mutated KRAS (pmKRAS) during the treatment of patients with advanced NSCLC; and ii) the prognostic value of baseline cfDNA and pmKRAS. Sixty‑nine patients were included in a prospective biomarker trial. Inclusion criteria included advanced NSCLC, candidate for first-line treatment, no previous cancer within the five years prior to this study. Blood samples were drawn at baseline, day 8 and at progression. Analyses of cfDNA and KRAS mutations in plasma were performed using an in-house qPCR assay. Evaluation of the treatment effect and status at follow-up was performed according to RECIST 1.1. The median levels of cfDNA were significantly higher at progression (9,250 alleles/ml) than at baseline (5,450 alleles/ml). Overall survival and progression-free survival were both significantly shorter in patients with high levels of cfDNA (above the 75th percentile) compared to lower levels. Only few patients harboured KRAS mutations in plasma. Two patients had no KRAS mutations in plasma at baseline, but mutations appeared in the subsequent blood samples. High baseline levels of cfDNA indicate a poor prognosis. The level changes during the treatment course with a significant increase at progression, suggesting a possible predictive value of cfDNA. The plasma KRAS status may change during treatment with potential implications for treatment selection.

View Figures

View References

1	Engholm G, Ferlay J, Christensen N, et al: NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.3 (25.04.2013). Association of the Nordic Cancer Registries. Danish Cancer Society. http://www.ancr.nu. Accessed March 2013
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v2.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer; Lyon: 2010, http://globocan.iarc.fr. Accessed March 2013
3	Hirsch FR, Janne PA, Eberhardt WE, et al: Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 8:373–384. 2013.PubMed/NCBI
4	D’arcangelo M, Wynes MW and Hirsch FR: The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 25:121–129. 2013.PubMed/NCBI
5	Sasaki T, Rodig SJ, Chirieac LR and Janne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 46:1773–1780. 2010. View Article : Google Scholar : PubMed/NCBI
6	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
7	Mok TS: Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol. 8:661–668. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kuang Y, Rogers A, Yeap BY, et al: Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res. 15:2630–2636. 2009. View Article : Google Scholar : PubMed/NCBI
9	Stroun M, Maurice P, Vasioukhin V, et al: The origin and mechanism of circulating DNA. Ann NY Acad Sci. 906:161–168. 2000. View Article : Google Scholar : PubMed/NCBI
10	Catarino R, Coelho A, Araujo A, et al: Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One. 7:e385592012. View Article : Google Scholar : PubMed/NCBI
11	Gautschi O, Bigosch C, Huegli B, et al: Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 22:4157–4164. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF and Jakobsen A: Quantification of cell free DNA as a prognostic factor in advanced NSCLC. J Can Ther. 4:1–7. 2013.
13	Sirera R, Bremnes RM, Cabrera A, et al: Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol. 6:286–290. 2011. View Article : Google Scholar : PubMed/NCBI
14	Spindler KL, Pallisgaard N, Vogelius I and Jakobsen A: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 18:1177–1185. 2012.
15	van der Drift MA, Hol BE, Klaassen CH, et al: Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer. 68:283–287. 2010.PubMed/NCBI
16	Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF and Jakobsen A: The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 79:312–317. 2013. View Article : Google Scholar : PubMed/NCBI
17	Punnoose EA, Atwal S, Liu W, et al: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 18:2391–2401. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kumar S, Guleria R, Singh V, Bharti AC, Mohan A and Das BC: Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 36:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
19	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
20	Steffensen KD, Waldstrom M, Grove A, Lund B, Pallisgard N and Jakobsen A: Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. Int J Gynecol Cancer. 21:1592–1600. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sozzi G, Conte D, Mariani L, et al: Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61:4675–4678. 2001.PubMed/NCBI
22	Kumar S, Guleria R, Singh V, Bharti AC, Mohan A and Das BC: Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer. 70:211–217. 2010. View Article : Google Scholar : PubMed/NCBI